Research Analysts Issue Forecasts for MRKR FY2024 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Analysts at Brookline Capital Management issued their FY2024 earnings estimates for shares of Marker Therapeutics in a research report issued on Monday, February 10th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of ($0.25) for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.05) per share.

Separately, LADENBURG THALM/SH SH boosted their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Stock Performance

NASDAQ:MRKR opened at $1.59 on Thursday. The company has a fifty day moving average of $2.88 and a two-hundred day moving average of $3.24. Marker Therapeutics has a fifty-two week low of $1.48 and a fifty-two week high of $5.99.

Insider Activity

In other Marker Therapeutics news, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the transaction, the insider now owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. The trade was a 51.73 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Steve Elms acquired 11,085 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, with a total value of $35,472.00. Following the acquisition, the director now owns 325,370 shares in the company, valued at $1,041,184. The trade was a 3.53 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 17.35% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invst LLC acquired a new stake in shares of Marker Therapeutics in the third quarter valued at approximately $56,000. LPL Financial LLC purchased a new position in shares of Marker Therapeutics during the 4th quarter worth $248,000. Finally, Aisling Capital Management LP raised its holdings in shares of Marker Therapeutics by 3.5% during the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after acquiring an additional 11,084 shares during the period. 22.39% of the stock is currently owned by institutional investors and hedge funds.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.